Ken Griffin Lineage Cell Therapeutics, Inc. Put Options Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
Put Options
3 transactions
Others Institutions Holding LCTX
# of Institutions
124Shares Held
93.5MCall Options Held
21.4KPut Options Held
0-
Broadwood Capital Inc New York, NY41.7MShares$37.1 Million4.66% of portfolio
-
Black Rock Inc. New York, NY8.49MShares$7.56 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.37MShares$7.45 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA6.25MShares$5.56 Million0.86% of portfolio
-
Defender Capital, Llc.4.97MShares$4.42 Million2.61% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $151M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...